Protein Kinase Ck2

by Pinna, Lorenzo A.

• ISBN13: 9780470963036
• ISBN10: 0470963034
• Edition: 1st
• Format: Hardcover
• Copyright: 2013-01-14
• Publisher: Wiley-Blackwell

Summary

The importance of CK2 in cancer and other diseases has generated a significant amount of literature on the protein, and an international community of CK2 researchers. The International Union of Biochemistry and Molecular Biology (IUMBMB) sponsors periodic international conferences on CK2, making the protein a natural topic for a Wiley-IUBMB publication. Protein Kinase CK2 will deal with structural aspects underlying the constitutive activity of CK2, its specific susceptibility to pharmacological inhibition and its extraordinary pleiotropy. In the second part the fundamental role of CK2 in a wide number of biological functions will be illustrated, while the third part will be devoted to the unusual mode of implication of CK2 in neoplastic transformation, with an appendix reviewing its potential relevance to other pathologies.

Author Biography

Lorenzo A. Pinna received his B. Sc. in Biochemistry from the University of Padova in 1962. From 1965-66 he was postdoctoral fellow at the Department of Physiological Chemistry, Johns Hopkins University Medical School, Baltimore, USA. In 1975 he was appointed Professor of Medical Chemistry and Biochemistry and in 1988 Director of the Department of Biological Chemistry at the University of Padova. A pioneer in the field of CK2 research, his research interests encompass various aspects of protein phosphorylation, with special reference to the design of synthetic peptide substrates for the specific monitoring of protein kinases and the assessment of the biological role and pathogenic potential of protein kinase CK2.

Table of Contents

PART I: INTRODUCTION
1. “CK2, a protein kinase for all seasons” (Lorenzo A. Pinna Dept. Biological Chemistry, University of Padua, Padua, Italy.

PART II: MOLECULAR AND STRUCTURAL ASPECTS
2. “CK2 structures in the light of the spine concept of eukaryotic protein kinases “ (Karsten Niefind, University of Cologne, Institute of Biochemistry, Cologne, Germany. E

3. “Structural bases for CK2 inhibition” (Roberto Battistutta, Department of Chemistry, University of Padua- Padova, Italy.

4. “The interactome of protein kinase CK2” (Mathias Montenarth, University of the Saarland, Medical Biochemistry and Molecular Biology, Homburg, Germany.

5. “The phosphoproteome generated by protein kinase CK2” (Mauro Salvi & Lorenzo A. Pinna Dept. Biological Chemistry, University of Padua, Padua, Italy.

PART III: FUNCTIONAL ASPECTS
6. “Intersection of CK2 with other signalling pathways” (David Litchfield, University of Western Ontario, Department of Biochemistry, London, Ontario, Canada.

7. “The role of protein kinase CK2 in the p53 response” (David W. Meek, University of Dundee, Biomedical Research Institute Ninewells Hospital, Dundee, UK.

8. “CK2 in embryonic development” (Isabel Dominguez, Boston University School of Medicine, Boston, MA, USA.

9. “Role of CK2 in the control of epithelial cell plasticity” (Claude Cochet, INSERM U873 iRTSV- CEA Grenoble, France.

10. “CK2 and circadian rhythm” 

11. “The pivotal role of CK2 in chaperoning the kinome” (Yoshihiko Miyata, Kyoto University, Dept. Cell & Develop. Biology, Kyoto, Japan.

12. “CK2: a global regulator of cell survival” (Olaf-G. Issinger, University of Southern Denmark, Institute of Biochemistry and Molecular Biology, Odense, Denmark.

13. “Specific features of plant CK2” (Montserrat Pages, CSIC, CRAG, Barcelona, Spain.

PART IV: CK2 AND NEOPLASIA

14. “The oncogenic potential of CK2” (David C. Seldin, Boston University Medical Center, Department of Medicine, Boston MA, USA.

15. “CK2 suppression of apoptosis and its implication in cancer biology and therapy” (Khalil Ahmed, University of Minnesota and V.A. Medical Center, Minneapolis, MN, USA.

16. “Abnormal levels of CK2 and the generation of cancer “addiction” (Maria Ruzzene, Dept. Biological Chemistry, University of Padua, Padua, Italy.

17. “CK2 as an ideal target in cancer therapy: combining inhibitors of CK2 with various classes of chemotherapeutic agents” (Kenna Anderes, Cylene Pharmaceuticals, Cancer Biology, San Diego, CA, USA.

18. “ CK2 in normal and malignant hematopoiesis” (Francesco Piazza, Venetian Institute of Molecular Medicine – VIMM, Padova, Italy.